Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab

Hematological Oncology

Volumn 31, Issue 1, 2013, Pages 10-17

  Papageorgiou, Sotirios G ^a   Diamantopoulos, Panayiotis ^b   Levidou, Georgia ^b   Angelopoulou, Maria K ^b   Economopoulou, Panagiota ^a   Efthimiou, Anna ^b   Constantinou, Nikos ^c   Katsigiannis, Andreas ^b   Korkolopoulou, Penelope ^b   Pappa, Vassiliki ^a   Economopoulou, Christina ^a   Georgiou, George ^b   Dimou, Maria ^b   Tsirigotis, Panagiotis ^a   Kyrtsonis, Marie Christine ^b   Kotsianidis, Ioannis ^d   Kalpadakis, Christina ^e   Dimopoulos, Meletios Athanassios ^b   Beris, Photis ^b   Meletis, John ^b   Pangalis, Gerassimos A ^f   Dervenoulas, John ^a   Panayiotidis, Panayiotis ^b   Vassilakopoulos, Theodoros P ^b   more..

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c THEAGENIO CANCER HOSPITAL   (Greece)

^d DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^e UNIVERSITY OF CRETE   (Greece)

^f ATHENS MEDICAL CENTER   (Greece)

Author keywords

Central nervous system; CHOP; Large B cell lymphoma; Primary mediastinal; Relapse; Rituximab

Indexed keywords

ALBUMIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; PREDNISONE; RITUXIMAB; THIOTEPA; VINCRISTINE;

ADOLESCENT; ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CANCER TRANSPLANTATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; GREECE; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; RADIATION DOSE; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BUSULFAN; CARMUSTINE; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MEDIASTINAL NEOPLASMS; METHOTREXATE; METHYLPREDNISOLONE; MIDDLE AGED; PREDNISONE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; THIOTEPA; VINCRISTINE; YOUNG ADULT;

EID: 84874934591     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2012     Document Type: Article

References (29)

1. Gaulard P, Harris NL, Pileri SA, et al. Primary mediastinal (thymic) large B-cell lymphoma. In World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues (4th edn), Swerdlow SH, Campo E, Harris NL, et al. (eds). Lyon IARC Press: France, 2008; 250-251.
2. Banks PM, Warnke RA. Mediastinal (thymic) large B-cell lymphoma. In World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). Lyon IARC Press: France, 2001; 175-176.
3. Savage KJ. Primary mediastinal large B-cell lymphoma. Oncologist 2006; 11: 488-495.
4. Hill QA, Owen RG. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 2006; 20: 319-332.
5. Bishop PC, Wilson WH, Pearson D, Janik J, Jaffe E, Elwood P. CNS involvement in primary mediastinal large B-cell lymphoma. J Clin Oncol 1999; 17: 2479-2485.
6. Vassilakopoulos TP, Pangalis GA, Katsigiannis A, et al. Rituximab, cyclophosphamide, doxorubicine, vincristine and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard therapy. Oncologist 2012; 17: 239-249.
7. Dunleavy K, Pittaluga S, Janik J, et al. The addition of rituximab to dose adjusted (DA)-EPOCH obviates the need for radiation in the treatment of primary mediastinal large B-cell lymphoma (PMBL): a prospective study of 58 patients. Ann Oncol 2008; 19(S.4): 96 abstr 043.
8. Ahn HK, Kim SJ, Yun J, et al. Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients. Int J Hematol 2010; 91: 456-463.
9. Rieger M, Osterborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol 2011; 22: 664-670.
10. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
11. Pangalis GA, Vassilakopoulos TP, Michalis E, et al. A randomized trial comparing intensified CNOP versus CHOP in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44: 635-644.
12. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Statist Assoc 1999; 94: 496-509.
13. Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 2010; 21: 1046-1052.
14. Sasaki M, Sugimoto K, Masuda A, Tsukune Y, Yahata Y, Komatsu N. Early CNS relapse in a good-risk primary mediastinal large B-cell lymphoma after combined chemo- and radio-therapy. J Neurooncol 2010; 99: 295-296.
15. Stefoni V, Broccoli A, Pellegrini C, Derenzini E, Fina M, Zinzani P. CNS recurrence of primary mediastinal large B-cell lymphoma after complete remission. J Neurooncol 2009; 95: 135-139.
16. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without Rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2009; 113: 3896-3902.
17. Schmitz N, Zeynalova S, Glass B, et al. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol 2011 Oct 11. doi: 10.1093/annonc/mdr440
18. Shimazu Y, Notohara K, Ueda Y. Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. Int J Hematol 2009; 89: 577-583.
19. Kridel R, Dietrich PY. Prevention of CNS relapse in diffuse large B-cell lymphoma. Lancet Oncol 2011; 12: 1258-1266.
20. van Besien K, Ha CS, Murphy S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998; 91: 1178-1184.
21. Haioun C, Besson C, Lepage E, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 2000; 11: 685-690.
22. Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 2002; 13: 1099-1107.
23. Doolittle ND, Abrey LE, Shenkier TN, et al. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood 2008; 111: 1085-1093.
24. Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007; 18: 149-157.
25. Zinzani PL, Magagnoli M, Frezza G, et al. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience. Leuk Lymphoma 1999; 32: 571-576.
26. Feugier P, Virion JM, Tilly H, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 2004; 15: 129-133.
27. Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol 2011; 90: 809-818.
28. Yamamoto W, Tomita N, Watanabe R, et al. Central nervous system involvement in diffuse large B-cell lymphoma. Eur J Haematol 2010; 85: 6-10.
29. Salzburg J, Burkhardt B, Zimmermann M, et al. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group report. J Clin Oncol 2007; 25: 3915-3922.